Founder

Kemp Dolliver, CFA

Cherrystone Hill Research

Equity Capital Markets

<p>This Insight is a brief follow-up to our prior Insight <a href="https://www.smartkarma.com/insights/antengene-gunning-to-move-up-in-line" target="_blank" data-smartkarma-citation="insights:44790" rel="noopener">Antengene: Gunning To Move Up in Line</a> which discusses the company in greater detail. In brief, we would take the deal. The offering puts a pre-money valuation of the company at the low end of the US$1-2 billion range mentioned in our prior Insight. In addition, the results of the SEAL trial tops up the market opportunity for ATG-010 (XPOVIO).</p>

This Insight is a brief follow-up to our prior Insight Antengene: Gunning To Move Up in Line which discusses the company in greater detail. In brief, we would take the deal. The offering puts a pre-money valuation of the company at the low end of the US$1-2 billion range mentioned in our prior Insight. In addition, the results of the SEAL trial tops up the market opportunity for ATG-010 (XPOVIO).

Antengene

Antengene: We Like the Deal